1. Home
  2. CUE vs LICN Comparison

CUE vs LICN Comparison

Compare CUE & LICN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • LICN
  • Stock Information
  • Founded
  • CUE 2014
  • LICN 2004
  • Country
  • CUE United States
  • LICN China
  • Employees
  • CUE N/A
  • LICN N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • LICN
  • Sector
  • CUE Health Care
  • LICN
  • Exchange
  • CUE Nasdaq
  • LICN Nasdaq
  • Market Cap
  • CUE 48.0M
  • LICN 3.0M
  • IPO Year
  • CUE 2018
  • LICN 2023
  • Fundamental
  • Price
  • CUE $0.69
  • LICN $4.18
  • Analyst Decision
  • CUE Strong Buy
  • LICN
  • Analyst Count
  • CUE 3
  • LICN 0
  • Target Price
  • CUE $3.00
  • LICN N/A
  • AVG Volume (30 Days)
  • CUE 312.0K
  • LICN 70.7K
  • Earning Date
  • CUE 08-13-2025
  • LICN 01-01-0001
  • Dividend Yield
  • CUE N/A
  • LICN N/A
  • EPS Growth
  • CUE N/A
  • LICN N/A
  • EPS
  • CUE N/A
  • LICN N/A
  • Revenue
  • CUE $7,991,000.00
  • LICN $41,477,000.00
  • Revenue This Year
  • CUE N/A
  • LICN N/A
  • Revenue Next Year
  • CUE $23.84
  • LICN N/A
  • P/E Ratio
  • CUE N/A
  • LICN N/A
  • Revenue Growth
  • CUE 13.83
  • LICN 4.32
  • 52 Week Low
  • CUE $0.45
  • LICN $2.60
  • 52 Week High
  • CUE $1.99
  • LICN $488.00
  • Technical
  • Relative Strength Index (RSI)
  • CUE 50.62
  • LICN 46.64
  • Support Level
  • CUE $0.65
  • LICN $4.00
  • Resistance Level
  • CUE $0.88
  • LICN $4.38
  • Average True Range (ATR)
  • CUE 0.08
  • LICN 0.26
  • MACD
  • CUE 0.01
  • LICN 0.01
  • Stochastic Oscillator
  • CUE 45.21
  • LICN 60.00

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

About LICN Lichen China Limited

Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and sales of financial and taxation training software.

Share on Social Networks: